• 1
    Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical uses. Exp Hematol 2000;28:875884.
  • 2
    Aubin JE. Bone stem cells. J Cell Biochem Suppl 1998;30–31:7382.
  • 3
    Idris AI, Sophocleous A, Landao-Bassonga E et al. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 2009;10:139147.
  • 4
    Nuttall ME, Gimble JM. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr Opin Pharmacol 2004;4:290294.
  • 5
    Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: Cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009;66:236253.
  • 6
    Backesjo CM, Li Y, Lindgren U et al. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs 2009;189:9397.
  • 7
    Menuki K, Mori T, Sakai A et al. Climbing exercise enhances osteoblast differentiation and inhibits adipogenic differentiation with high expression of PTH/PTHrP receptor in bone marrow cells. Bone 2008;43:613620.
  • 8
    Thomas T, Gori F, Khosla S et al. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 1999;140:16301638.
  • 9
    Guntur AR, Kawai M, Le P et al. An essential role for the circadian-regulated gene nocturnin in osteogenesis: The importance of local timekeeping in skeletal homeostasis. Ann N Y Acad Sci 2011;1237:5863.
  • 10
    Post S, Abdallah BM, Bentzon JF et al. Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells. Bone 2008;43:3239.
  • 11
    Cui X, Wang H, Guo H et al. Transplantation of mesenchymal stem cells preconditioned with diazoxide, a mitochondrial ATP-sensitive potassium channel opener, promotes repair of myocardial infarction in rats. Tohoku J Exp Med 2010;220:139147.
  • 12
    Gao C, Seuntjens J, Kaufman GN et al. Mesenchymal stem cell transplantation to promote bone healing. J Orthop Res 2012;30:11831189.
  • 13
    Guan M, Yao W, Liu R et al. Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med 2012;18:456462.
  • 14
    Komori T. Regulation of osteoblast differentiation by Runx2. Adv Exp Med Biol 2010;658:4349.
  • 15
    Komori T. Cbfa1/Runx2, an essential transcription factor for the regulation of osteoblast differentiation. Nihon Rinsho 2002;60( Suppl 3):9197.
  • 16
    Franceschi RT, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways. J Cell Biochem 2003;88:446454.
  • 17
    Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998;78:783809.
  • 18
    Savopoulos C, Dokos C, Kaiafa G et al. Adipogenesis and osteoblastogenesis: Trans-differentiation in the pathophysiology of bone disorders. Hippokratia 2011;15:1821.
  • 19
    Khatiwala CB, Kim PD, Peyton SR et al. ECM compliance regulates osteogenesis by influencing MAPK signaling downstream of RhoA and ROCK. J Bone Miner Res 2009;24:886898.
  • 20
    Shi Y, Li H, Zhang X et al. Continuous cyclic mechanical tension inhibited Runx2 expression in mesenchymal stem cells through RhoA-ERK1/2 pathway. J Cell Physiol 2011;226:21592169.
  • 21
    Kim SP, Ha JM, Yun SJ et al. Transcriptional activation of peroxisome proliferator-activated receptor-gamma requires activation of both protein kinase A and Akt during adipocyte differentiation. Biochem Biophys Res Commun 2010;399:5559.
  • 22
    Yu WH, Li FG, Chen XY et al. PPARgamma suppression inhibits adipogenesis but does not promote osteogenesis of human mesenchymal stem cells. Int J Biochem Cell Biol 2012;44:377384.
  • 23
    Tontonoz P, Hu E, Graves RA et al. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994;8:12241234.
  • 24
    Ren D, Collingwood TN, Rebar EJ et al. PPARgamma knockdown by engineered transcription factors: Exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002;16:2732.
  • 25
    Ferrari D, Gulinelli S, Salvestrini V et al. Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Exp Hematol 2011;39:360374.
  • 26
    Gallagher JA. ATP P2 receptors and regulation of bone effector cells. J Musculoskelet Neuronal Interact 2004;4:125127.
  • 27
    Gallagher JA, Buckley KA. Expression and function of P2 receptors in bone. J Musculoskelet Neuronal Interact 2002;2:432439.
  • 28
    Hoebertz A, Arnett TR, Burnstock G. Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol Sci 2003;24:290297.
  • 29
    Coppi E, Pugliese AM, Urbani S et al. ATP modulates cell proliferation and elicits two different electrophysiological responses in human mesenchymal stem cells. Stem Cells 2007;25:18401849.
  • 30
    Noronha-Matos JB, Costa MA, Magalhaes-Cardoso MT et al. Role of ecto-NTPDases on UDP-sensitive P2Y(6) receptor activation during osteogenic differentiation of primary bone marrow stromal cells from postmenopausal women. J Cell Physiol 2012;227:26942709.
  • 31
    Alvarenga EC, Rodrigues R, Caricati-Neto A et al. Low-intensity pulsed ultrasound-dependent osteoblast proliferation occurs by via activation of the P2Y receptor: Role of the P2Y1 receptor. Bone 2010;46:355362.
  • 32
    Lazarowski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 2003;64:785795.
  • 33
    Abbracchio MP, Burnstock G, Boeynaems JM et al. International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006;58:281341.
  • 34
    Fabre AC, Malaval C, Ben Addi A et al. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 2010;52:14771483.
  • 35
    Marteau F, Le Poul E, Communi D et al. Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 2003;64:104112.
  • 36
    Communi, D, Gonzalez NS, Detheux M et al. Identification of a novel human ADP receptor coupled to G(i). J Biol Chem 2001;276:4147941485.
  • 37
    Orriss I, Syberg S, Wang N et al. Bone phenotypes of P2 receptor knockout mice. Front Biosci (Schol Ed) 2011;3:10381046.
  • 38
    Orriss IR, Wang N, Burnstock G et al. The P2Y(6) receptor stimulates bone resorption by osteoclasts. Endocrinology 2011;152:37063716.
  • 39
    Wang N, Robaye B, Agrawal A et al. Reduced Bone Turnover in Mice Lacking the P2Y13 Receptor of ADP. Mol Endocrinol 2012;26:142152.
  • 40
    Orriss IR, Utting JC, Brandao-Burch A et al. Extracellular nucleotides block bone mineralization in vitro: Evidence for dual inhibitory mechanisms involving both P2Y2 receptors and pyrophosphate. Endocrinology 2007;148:42084216.
  • 41
    Dobson KR, Reading L, Haberey M et al. Centrifugal isolation of bone marrow from bone: An improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int 1999;65:411413.
  • 42
    Dumas A, Le Drevo MA, Moreau MF et al. Isolation of osteoprogenitors from murine bone marrow by selection of CD11b negative cells. Cytotechnology 2008;58:163171.
  • 43
    Heath DJ, Chantry AD, Buckle CH et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009;24:425436.
  • 44
    McBeath R, Pirone DM, Nelson CM et al. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell 2004;6:483495.
  • 45
    Malaval C, Laffargue M, Barbaras R et al. RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes. Cell Signal 2009;21:120127.
  • 46
    Kukulski F, Levesque SA, Lavoie EG et al. Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8. Purinergic Signal 2005;1:193204.
  • 47
    Wilkison WO, Min HY, Claffey KP et al. Control of the adipsin gene in adipocyte differentiation.Identification of distinct nuclear factors binding to single- and double-stranded DNA. J Biol Chem 1990;265:477482.
  • 48
    Zippel N, Limbach CA, Ratajski N et al. Purinergic receptors influence the differentiation of human mesenchymal stem cells. Stem Cells Dev 2012;21:884900.
  • 49
    Costessi A, Pines A, D'Andrea P et al. Extracellular nucleotides activate Runx2 in the osteoblast-like HOBIT cell line: A possible molecular link between mechanical stress and osteoblasts' response. Bone 2005;36:418432.
  • 50
    Pirraco RP, Reis RL, Marques AP. Effect of monocytes/macrophages on the early osteogenic differentiation of hBMSCs. J Tissue Eng Regen Med 2013;7:392400.
  • 51
    Lazarowski ER. Vesicular and conductive mechanisms of nucleotide release. Purinergic Signal 2012;8:359373.
  • 52
    Glaser T, Cappellari AR, Pillat MM et al. Perspectives of purinergic signaling in stem cell differentiation and tissue regeneration. Purinergic Signal 2012;8:523537.
  • 53
    Syberg S, Brandao-Burch A, Patel JJ et al. Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. J Bone Miner Res 2012;27:23732386.
  • 54
    Takedachi M, Oohara H, Smith BJ et al. CD73-generated adenosine promotes osteoblast differentiation. J Cell Physiol 2012;227:26222631.
  • 55
    Carroll SH, Wigner NA, Kulkarni N et al. A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J Biol Chem 2012;287:1571815727.
  • 56
    Kawai M, Namba N, Mushiake S et al. Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARgamma pathway. J Mol Endocrinol 2007;38:1934.
  • 57
    Jia B, Madsen L, Petersen RK et al. Activation of protein kinase A and exchange protein directly activated by cAMP promotes adipocyte differentiation of human mesenchymal stem cells. Plos One 2012;7:e34114.
  • 58
    Garnero P, Sornay-Rendu E, Chapuy MC et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337349.
  • 59
    Meunier P, Aaron J, Edouard C et al. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue.A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 1971;80:147154.
  • 60
    Burkhardt R, Kettner G, Bohm W et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary |osteoporosis, and old age: A comparative histomorphometric study. Bone 1987;8:157164.